Previous 10 | Next 10 |
Shares of Orphazyme (NASDAQ: ORPH) skyrocketed 24.6% as of the market close on Wednesday after rising as much as 56.6% earlier in the day. The big gain came after the drugmaker announced that Goldman Sachs (NYSE: GS) temporarily increased its stake to 5.58% on Jun. 16, 2021,...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Orphazyme (NASDAQ: ORPH ) have seen absolutely massive gains. Shares of OPRH stock peaked as high as $9.35, representing a gain of nearly 57% from yesterday’s close. However, ORPH ...
Current & Former Biotech Penny Stocks To Watch Right Now When it comes to hot sectors to watch in the stock market this year, biotech is definitely one that comes to mind. Thanks to excitement stemming from countless penny stocks , the mix of volatility and trading action have f...
Gainers: Entera Bio (ENTX) +56%. Orphazyme (ORPH) +47%. Bellerophon Therapeutics (BLPH) +26%. HUTCHMED (HCM) +11%. Evaxion Biotech (EVAX) +8%.Losers: Gemini Therapeutics (GMTX) -32%. Second Sight Medical Products (EYES) -19%. Millendo Therapeutics (MLND) -17...
AndrewJohnson/E+ via Getty Images After three consecutive days of losses, Danish biotech Orphazyme ([[ORPH]] +35.5%) is on track to recovery after announcing that Goldman Sachs Group briefly exceeded the 5% threshold of share ownership at the company. “…As of June 16, 2021, The ...
Gainers: Idera Pharmaceuticals (IDRA) +22%, Beyond Air (XAIR) +14%, Clover Health Investments (CLOV) +14%, Adial Pharmaceuticals (ADIL) +13%, CollPlant Biotechnologies (CLGN) +10%.Losers: Mereo BioPharma (MREO) -9%, Portage Biotech (PRTG) -9%, ...
Hopes were high for Orphazyme’s arimoclomol following FDA’s controversial decision on Alzheimer’s therapy aducanumab. However, the agency has rejected arimoclomol, and the company released weak guidance for 2021. Orphazyme needs to tap the equity markets relat...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In another one of the wild (and arguably unpredictable) adventures of coordinated trading on Reddit , biotechnology firm Orphazyme (NASDAQ: ORPH ) recently produced more gyrations on its technical chart than robust s...
Ole Schwander/iStock via Getty Images Orphazyme cut to sell at Guggenheim after regulatory snub Orphazyme (ORPH) is trading ~3.4% higher in the pre-market today after losing more than 50% on Friday in reaction to its failure to win FDA approval for arimoclomol. With a $1.00 pri...
Shares of Denmark-based biopharmaceutical company Orphazyme’s (ORPH) experienced extreme volatility this month due to the actions of retail traders that were triggered by discussions about the stock on social media platforms such as Reddit. After hitting its $4.75 all-time low on June ...
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...